Citalopram for Cocaine Dependence
| Status: | Completed |
|---|---|
| Conditions: | Psychiatric, Pulmonary |
| Therapuetic Areas: | Psychiatry / Psychology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - 60 |
| Updated: | 5/5/2017 |
| Start Date: | December 2010 |
| End Date: | July 2016 |
Clinical Trial of Serotonin Medication Combination in Cocaine Dependence
This is a phase 2 clinical trial of citalopram pharmacotherapy for treatment of cocaine
dependence. Using a double-blind, randomized controlled design, eligible cocaine dependent
patients will be assigned equally to one of three medication conditions: placebo or the
Selective serotonin re-uptake inhibitor (SSRI) agent, citalopram at either 20 mg per day or
40 mg per day. It is hypothesized that citalopram will reduce cocaine use and increase
periods of sustained abstinence substantially more than placebo. Performance on a set of
behavioral tasks of impulsivity will be analyzed as potential predictors of treatment
response.
dependence. Using a double-blind, randomized controlled design, eligible cocaine dependent
patients will be assigned equally to one of three medication conditions: placebo or the
Selective serotonin re-uptake inhibitor (SSRI) agent, citalopram at either 20 mg per day or
40 mg per day. It is hypothesized that citalopram will reduce cocaine use and increase
periods of sustained abstinence substantially more than placebo. Performance on a set of
behavioral tasks of impulsivity will be analyzed as potential predictors of treatment
response.
Inclusion Criteria:
- between 18 and 60 years of age
- meet Diagnostic and Statistical Manual 4 (DSM-IV) criteria for current cocaine
dependence
- be in acceptable health on the basis of interview, medical history and physical exam
- able to provide the names of at least 2 persons who can generally locate their
whereabouts.
Exclusion Criteria:
- diagnosis of any psychoactive substance dependence other than cocaine, marijuana, or
nicotine
- have a psychiatric disorder or neurological disease or disorder requiring ongoing
treatment and/or making study participation unsafe
- medical conditions contraindicating citalopram pharmacotherapy
- taking medications known to have significant drug interactions with the study
medication
- pregnant or nursing for female patients
- having plans to leave the immediate geographical area within 3 months
We found this trial at
1
site
Houston, Texas 77054
Principal Investigator: Joy M Schmitz, Ph.D.
Phone: 713-500-3784
Click here to add this to my saved trials
